文献速递毛发、甲与色素性疾病

自体细胞采集装置为稳定期白癜风病灶提供复色并改善生活质量:一项大型多样化患者人群研究

Autologous cell harvesting device provides repigmentation and improves quality-of-life for patients with stable vitiligo lesions in a large and diverse patient population.
PubMed 文献 · J Am Acad Dermatol · 2025-03-28

该前瞻性多中心研究纳入107例稳定期白癜风患者,病灶激光消融后接受自体皮肤细胞悬液(ASCS)治疗并居家光疗。第4周即观察到≥80%的优良复色反应;第24周所有病灶均有改善,67%达到>50%复色,42%达到≥80%复色,8%完全复色。27.7%病灶达到白癜风显著度量表响应,72.3%患者报告治疗满意,第24周白癜风生活质量instrument较基线显著改善(P<.05)。

要点

  • ASCS治疗稳定期白癜风第24周67%病灶复色>50%,42%复色≥80%。
  • 第24周白癜风生活质量instrument较基线显著改善(P<.05)。
  • 72.3%患者报告治疗满意,27.7%病灶达到白癜风显著度量表响应。

核心结论

  • 细胞采集装置为黑素细胞移植提供了简化、更易普及的技术。
  • ASCS对稳定期白癜风病灶复色高度有效,患者报告结局积极且生活质量改善。

研究设计与样本

  • 大型(N=107)前瞻性多中心研究。
  • 稳定期白癜风病灶经激光消融后接受ASCS治疗,随后居家光疗。

主要发现

  • 所有Fitzpatrick皮肤类型和主要白癜风亚型均有代表。
  • 第4周即观察到优良复色反应(≥80%)。
  • 第24周所有病灶均有改善,67%达到>50%复色,42%达到≥80%复色,8%完全复色。
  • 27.7%病灶达到白癜风显著度量表响应,72.3%患者报告治疗满意。
  • 第24周白癜风生活质量instrument较基线显著改善(P<.05)。

关键数值与推荐

  • 优良复色反应定义为≥80%复色。
  • 第24周67%病灶达到>50%复色,42%达到≥80%复色,8%完全复色。
  • 27.7%病灶达到白癜风显著度量表响应。
  • 72.3%患者报告治疗满意。
  • 第24周白癜风生活质量instrument较基线改善(P<.05)。

临床怎么用

  • ASCS可作为稳定期白癜风黑素细胞移植的简化选择。
  • 治疗后可配合居家光疗以促进复色。
  • 需关注患者报告的生活质量改善和治疗满意度。

局限性

  • 研究无对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The mental health burden associated with vitiligo can significantly impact patients' quality-of-life. Although successful for repigmentation of stable vitiligo, adoption of surgical melanocyte transplantation remains limited due to time and skilled-expertise requirements. A cell harvesting device prepares autologous skin cell suspension (ASCS) at point of care, simplifying the process. OBJECTIVE: To confirm early and favorable repigmentation response and evaluate health-related quality-of-life changes following ASCS treatment of stable vitiligo. METHODS: In this large (N = 107), prospective, multicenter study, vitiligo lesions were laser-ablated and received ASCS treatment followed by at-home phototherapy. RESULTS: All Fitzpatrick skin types and major vitiligo subtypes were represented. Excellent repigmentation response (≥80%) was observed by week 4. By week-24, all lesions demonstrated improvement; 67% achieved >50% repigmentation, 42% achieved ≥80% repigmentation, and 8% achieved complete repigmentation. Vitiligo Noticeability Scale response was attained by 27.7% of lesions; 72.3% of patients reported treatment satisfaction. Significant improvement from baseline in Vitiligo Quality-of-Life Instrument (P < .05) was observed at week-24. LIMITATIONS: No control. CONCLUSIONS: The cell harvesting device provides a simplified, more accessible technique for melanocyte transplantation. ASCS is highly effective for repigmentation of stable vitiligo lesions, with positive patient-reported outcomes and improvement in quality-of-life, as demonstrated in this large, diverse population.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Pandya AG, Mahmoud BH, Huggins RH, et al. Autologous cell harvesting device provides repigmentation and improves quality-of-life for patients with stable vitiligo lesions in a large and diverse patient population. J Am Acad Dermatol. 2025. PMID: 40158537. doi:10.1016/j.jaad.2025.03.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。